Équipe d'expertise-conseil médicale en oncologie et hématologie

Victor Angélico, MD
Directeur médical

Victor Angélico, MD, is senior medical director for Labcorp Clinical Development Services, based in Paris, France. He provides clinical and medical expertise to project teams and other Labcorp departments to advance clients' drug development programs. Dr. Angélico performs medical monitoring on assigned projects; reviews protocols, case report forms and other data and materials; and contributes to the scientific leadership of the Oncology area at Labcorp with a special focus in early phase clinical studies and hematological malignancies. Dr. Angélico is board certified in internal medicine and oncology with 16 years in the clinic and has significant medical and pharmaceutical expertise with 14 years of experience in the pharmaceutical industry. Before his current position, he served as senior medical officer for Chiltern France and as medical director at IQVIA France. Dr. Angélico joined Labcorp in January 2019.

Ariel E. Aguiló, MD
Directeur médical principal

Ariel Aguiló, MD, senior medical director for Labcorp Clinical Development Services in Buenos Aires, Argentina, is a board-certified oncologist specialized in GI tumors. He provides subject matter expertise and support for the development and conduct of clinical trials on clients' drug development projects, including serving as the company's subject matter expert for decentralized clinical trials (DCT). Dr. Aguiló performs medical monitoring on assigned projects, contributes to the medical strategy and execution of clinical programs and brings scientific strategic leadership to the Oncology area at Labcorp. Il compte 10 ans d'expérience en tant que médecin, conseiller médical et directeur médical dans la recherche et le développement de médicaments. Before joining Labcorp, he served as medical director for Syneos Health in Buenos Aires, and prior to that, he served as medical advisor for IQVIA in Buenos Aires. Dr. Aguiló began his career as attending physician, GI oncology department, Hospital de Gastroenterologia. He joined Labcorp in November 2019.

Liliana Baila, MD
Directrice médicale principale

Liliana Baila, MD, is senior medical director for Labcorp Clinical Development Services, based in Brussels, Belgium. Elle travaille comme médecin principale sur les projets de développement de médicaments de nos clients. Dr Baila fournit un soutien médical/scientifique aux équipes des projets, réalise le suivi médical et de sécurité sur les projets qui lui sont assignés, et développe et révise des protocoles, des formulaires de rapport de cas et d'autres données et documents. Dr Baila a plus de 25 ans d'expérience en tant que médecin, oncologue clinique et directrice médicale. Before joining Labcorp, she served as clinical research physician for the European Organisation for Research and Treatment of Cancer in Brussels. Dr Baila a commencé sa carrière de médecin comme interne en néonatologie et en pédiatrie dans un hôpital universitaire de Roumanie. She joined Labcorp in June 2020.

Maria Ignacia Berraondo, MD
Directrice médicale principale

Maria Ignacia Berraondo, MD, is senior medical director for Labcorp Clinical Development Services, based in Buenos Aires, Argentina. She provides clinical and medical expertise to project teams and other Labcorp departments to advance clients' drug development programs. Dr. Berraondo performs medical and safety monitoring on assigned projects; develops and reviews protocols, case report forms and other data and materials; and contributes to the scientific strategic leadership of the Oncology area at Labcorp. Dr Berraondo a plus de 10 ans d'expérience en hématologie et comme conseillère médicale et médecin, dont six ans en recherche clinique, notamment comme directrice de la recherche et du développement cliniques. Before joining Labcorp, she served as medical director at IQVIA in Buenos Aires. Dr. Berraondo joined Labcorp in July 2020.

Stefanella Bortini, MD, PhD
Directeur médical

Stefanella Bortini, MD, PhD, is senior medical director of oncology for Labcorp Clinical Development Services, based in Milano, Italy. She contributes to the development of Labcorp policies involving medical, safety and therapeutics and serves as global lead project physician on assigned projects. Dr. Bortini brings more than 30 years of experience in clinical research to Labcorp. Before joining the company, she was senior director, Medical Affairs, Oncology, for Chiltern International in Milan. She also has held positions with i3 Research, PRA International, Pharmacia & Upjohn, and Eli Lilly. Dr. Bortini is medically licensed by the Italian Board of Medical and Surgical Examiners and holds ECFMG Medical Certification for the U.S. She received her medical degree from the University of Firenze in Italy and her PhD in biomedical engineering from Northwestern University. She joined Labcorp in July 2019.

Patrícia Brandalise, MD, MsC
Clinical Oncologist

Patrícia Andrade Brandalise, MD, MsC, has been a boarded clinical oncologist in Brazil since 2005. Dr. Brandalise earned her MD and MsC degrees at State University of Campinas (UNICAMP), Brazil, and received her oncology qualifications at the Campinas Institute of Oncology. She is an active member of the Brazilian Society of Oncology. Dr. Brandalise has more than 18 years of experience in clinical oncology with clinical, investigational and administrative responsibilities and 15 years serving in the pharmaceutical industry. Before joining Labcorp, Dr. Brandalise worked for Janssen and AbbVie as medical director for Latin America in the hematology and oncology business unit. She also served as oncology medical leader for Roche Brazil, implementing several compassionate use programs in Latin America, preparing and delivering launches for new molecules/indications. She also has been designing and implementing Phase I-II-III-IV trials in Argentina, Brazil, Colombia, México, Peru, Argentina, Puerto Rico, Korea and Australia, many as lead physician. She joined Labcorp in April 2022.

Valery Chatikhine, MD, PhD

Medical Oncologist

Valery Chatikhine, MD, PhD, is a medical oncologist, board certified by the University of Paris — XI and Cancer Research Center of the Russian Academy of Medical Sciences, with more than 10 years of medical oncology clinical practice.

He is experienced in oncology drug development Phase I-III studies for multiple solid tumors and selected hematologic malignancies with small and large molecules (immuno-oncology), ADCs and T-cells and NK cells in solid tumors, glioblastoma and lymphoma with FDA- and EMA-relevant IND/NDAs/BLA submission and approval involvement.

In addition, Dr. Chatikhine is well published, with more than 40 publications in peer-reviewed journals (Journal of Clinical Oncology, American Journal of Clinical Oncology, European Journal of Clinical Oncology, Cancer Letters). He is an active member of the American Society of Clinical Oncology and Society for Neuro-Oncology. He joined Labcorp in April 2022.

Isagani M. Chico, MD
Vice President and Global Therapeutic Head

Isagani (Gani) M. Chico, MD, is vice president and global therapeutic head of oncology for Labcorp Clinical Development Services, based in Gaithersburg, Maryland. Dr. Chico has more than 30 years of experience in oncology clinical drug development from small- and medium-sized biotechnology companies, CROs and the FDA, focused on planning and execution of global oncology clinical development projects from early phase to postapproval, leadership of cross-functional strategic teams within medical affairs and clinical development organizations, and management of pharmaceutical, academic and regulatory interactions. Dr. Chico earned his medical degree from the University of the Philippines and completed his internal medicine residency at the Cook County Hospital in Chicago and medical oncology fellowship training at the National Institutes of Health in Bethesda, Maryland. He joined in Labcorp in July 2020.

Carolina Dutra, MD, MsC
Directrice médicale

Carolina Dutra, MD, MsC, is medical director for Labcorp Clinical Development Services, based in Brazil. She is a medical oncologist by training and provides clinical and medical expertise to project teams and other Labcorp departments to advance clients' drug development programs. Dr. Dutra performs medical and safety monitoring on assigned projects; develops and reviews protocols, case report forms and other data and materials; and contributes to the scientific strategic leadership of the Oncology area at Labcorp. Dr. Dutra has more than 15 years of experience as a physician and principal investigator. She joined Labcorp in May 2021.

Jose Espinoza
Senior Medical Director, Therapeutic Area/Oncology

Jose Espinoza has more than 20 years of experience in drug development, which includes enrolling patients into cancer trials, helping design and execute studies, conducting medical monitoring and data analysis of global trials, interfacing with regulatory bodies and working with biotech and pharmaceutical companies to refine drug development strategies. He worked at Pivotal with key opinion leaders to develop new protocols for the treatment of hematological malignancies with CAR T-cells. He served as the global medical monitor (U.S./EU) in the pivotal Phase II study for the accelerated FDA approval of melflufen in relapsed/refractory multiple myeloma in February 2021. Dr. Espinoza holds a double specialization-clinical oncology (1992-1997) and clinical hematology and bone marrow transplantation (1997-2001)-and has more than 20 years of clinical experience as consultant onco-hematologist at public hospitals in Spain and Ireland. He joined Labcorp in October 2021.

Jose Daniel Fanjul Fuente, MD
Directeur médical

Jose Daniel Fanjul Fuente, MD, is medical director of oncology for Labcorp Clinical Development Services, based in Madrid, Spain. He provides medical and scientific guidance and support to project teams and investigative sites on clients' drug development projects and reviews protocols, case report forms, clinical study reports, and other data and materials. Dr Fuente apporte plus de 10 années d'expérience en tant que médecin et directeur médical, spécialisé dans la recherche clinique et le développement en oncologie. Avant d'occuper son poste actuel, il a été directeur médical et responsable en oncologie chez IQVIA et Bristol Myers Squibb à Buenos Aires, en Argentine. At Bristol Myers Squibb, Dr. Fuente led scientific activities that gave impetus to the product line of the oncology therapeutic area (nivolumab and ipilimumab). He joined Labcorp in October 2018.

Begoña de las Heras Garcia, MD
Directrice médicale

Begoña de las Heras Garcia, MD, is senior medical director of oncology for Labcorp Clinical Development Services, based in Madrid, Spain. She is a board-certified medical oncologist, by La Paz Hospital, Madrid, Spain. At Labcorp, she serves as project physician on clients' drug development projects and provides medical/scientific expertise to project teams/business development teams. Also, she has line management activities in a group of MDs in the Oncology TA. She brings more than 20 years of national and international clinical oncology research experience to Labcorp. Before her current position, she served as executive medical officer, early phase, for Chiltern in the U.K. She also has held clinical research positions with Eisai in the U.K. and several organizations in Spain, including Pivotal CRO, PharmaMar, AstraZeneca and Bristol Myers Squibb. Additionally, she was oncologist consult in several hospitals in Spain: General Yagüe Hospital in Burgos, Nuestra Señora Del Prado Hospital in Talavera de la Reina (Toledo) and La Paz Hospital in Madrid. She joined Labcorp in 2016.

Franklin Gaylis, MD, FACS
Urology Consultant

Franklin Gaylis, MD, FACS, is a urology consultant at Labcorp Drug Development. He also serves as executive medical director of Unio Health Partners (UHP), the largest urology group in California, and as a voluntary professor of urology at the University of California, San Diego.

Dr. Gaylis is a fellow of the American College of Surgeons, member of the American Urological Association and diplomat of the American Board of Urology. He lectures nationally and internationally on the subject of medical quality and implementation science and is considered a leader in the field. His research has been published in clinical journals such as Urology, Journal of Urology, Urology Practice, American Journal of Medical Quality and the New England Journal of Medicine. Dr. Gaylis' practice of more than 30 years has been focused on treating early- and late-stage prostate and bladder cancer including surgical procedures as well as clinical trials, Phases I-IV. He has participated in numerous clinical trials over the past 30 years, serving as PI in many, and has 40 publications, 30 of which he is first author. Dr. Gaylis has a deep interest in data mining from the EMR and oversees UHP's healthcare informatics program. He has experience with "big data" analytics and is exploring the feasibility for developing synthetic/external controls in Urology at Labcorp. Dr. Gaylis provides urological guidance for therapeutics, diagnostics and biomarker clinical trials and has conducted several advisory boards for sponsors seeking guidance regarding protocols in development. He joined in Labcorp in 2020.

Brian Hamilton, MD, PhD
Directeur médical

Brian Hamilton, MD, PhD, is senior medical director for Labcorp Clinical Development Services, based in Newton, Massachusetts. He serves as Labcorp's subject matter expert for cellular immune-oncology, CAR T and gene therapy. Il est aussi responsable mondial des questions médicales des projets de développement de médicaments des clients. Dr Hamilton a plus de 35 ans d'expérience en médecine pédiatrique, immunologie, transplantation de cellules souches hématopoïétiques et recherche et développement cliniques. Before joining Labcorp, he served as executive medical monitor for Chiltern International. He also has held senior-level medical director, director physician, regulatory affairs and clinical research positions with Galena Biopharma, AstraZeneca, Onyx Pharmaceuticals, Wyeth Oncology and other pharmaceutical and biotech firms. Dr. Hamilton joined Labcorp in August 2018.

Konstantin Haradinov, MD
Directeur médical

Konstantin Haradinov, MD, is medical director of oncology for Labcorp Clinical Development Services, based in Sofia, Bulgaria. He contributes to the development of Labcorp policies involving medical, safety and therapeutics; serves as global lead project physician and provides medical and safety monitoring on assigned projects; reviews medical data and provides clinical and medical expertise to project teams and other Labcorp departments; and performs safety trend analyses. Dr Haradinov a plus de 15 ans d'expérience en recherche clinique en tant que directeur médical et médecin/oncologue. Before joining Labcorp, he served as medical officer for oncology at Chiltern International in Sofia, Bulgaria. Dr. Haradinov joined Labcorp in April 2019.

He Huang, MD
Directeur médical principal

He Huang, MD, is senior director of the Asia Pacific (APAC) region for Labcorp Clinical Development Services, based in Shanghai, China. He brings more than 10 years of experience as a physician and researcher in oncology, respiratory therapy and drug development to Labcorp. Before joining Labcorp, Dr. Huang served as disease area head for oncology/GI at Bristol Myers Squibb in Shanghai. He also served as senior manager for respiratory at AstraZeneca and medical manager for oncology/GI at Roche in Shanghai. Il a reçu le prix Global Champion and China CEO chez AstraZeneca. Dr. Huang began his career as medical oncologist at Affiliated Hospital of Tongji Medical College of Huazhong University of Science and Technology in Wuhan, China. He joined Labcorp in September 2019.

Adrianne Kelly, MD
Directrice médicale principale

Adrianne Kelly, MD, is a contracted senior medical director for Labcorp Clinical Development Services, based in Princeton, New Jersey, and chief medical officer of Jude, Peregrine and Kelly Consultants, LLC, in Bethesda, Maryland. Elle travaille comme médecin principale sur les projets de développement de médicaments de nos clients. Dr. Kelly provides medical/scientific feedback on protocols and clinical development plans, input on site feasibility relative to protocol requirements, medical monitoring on assigned projects and training to project teams. Elle a plus de 30 ans d'expérience comme médecin, chercheuse clinique et dans le développement de médicaments en hématologie et oncologie. Dr Kelly est diplômée en médecine de l'université de Georgetown et a reçu plus d'une douzaine de prix pour son leadership dans le monde de la santé et le milieu universitaire. Dr. Kelly joined Labcorp in August 2010.

Geoffrey Kannan, MD, PhD
Directeur médical

Geoffrey Kannan, MD, PhD, is a senior medical director in the Oncology Therapeutic Area for Labcorp Clinical Development Services, based in Princeton, New Jersey. Dr Kannan est responsable mondial des projets de développement de médicaments des clients, fournissant une expertise médicale et un soutien dans le développement et la conduite d'essais cliniques. Dr. Kannan brings more than 10 years of experience as a physician and medical director to Labcorp, specializing in oncology and pediatrics. Before joining Labcorp, he practiced as pediatric hematologist/oncologist and pediatric neuro-oncologist affiliated with Children's National Medical Center. Prior to that, he served as instructor of pediatrics and pediatric neuro-oncologist for the department of pediatric neuro-oncology at Dana-Farber Cancer Institute/Boston Children's Hospital/Harvard Medical School. The author or co-author of many peer-reviewed journal articles, presentations and abstracts, Dr. Kannan joined Labcorp in November 2018.

Carlo Lanza, MD, PhD
Médecin-chef de service

Carlo Lanza, MD, PhD, is executive medical officer for Labcorp Clinical Development Services, based in Lugano, Switzerland. Dr. Lanza performs medical monitoring and safety assessments on Phase I-IV clinical trials for Labcorp clients. Il dirige des programmes de développement en phase précoce et de recherche translationnelle sur les thérapies ciblées, les petites molécules, les médicaments biologiques et la thérapie génique. Dr. Lanza also oversees development of late-stage development strategies and delivery and approval of registrational programs. Il apporte plus de 20 années d'expérience dans la recherche et le développement cliniques en tant que médecin et directeur médical, spécialisé en pédiatrie et en oncologie. Before joining Labcorp, he served as medical director for medicines at Malaria Venture in Geneva, Switzerland. Dr. Lanza also has held leadership positions with Novartis Oncology, Pfizer Global Research and Development, and AstraZeneca U.K. He joined Labcorp in 2012.

Zarah Dulce Lucas, MD
Directeur médical

Zarah Dulce Lucas, MD, is a senior medical director in the Oncology Therapeutic Area for Labcorp Clinical Development Services, based in Princeton, New Jersey. Dr. Lucas serves as global lead project physician on clients' drug development projects; performs medical and safety monitoring on assigned projects; develops and reviews protocols, case report forms and other data and materials; and contributes to the scientific strategic leadership of the Oncology area at Labcorp. Dr. Lucas brings more than 10 years of experience as a physician, specializing in internal medicine, medical oncology and hematology. Prior to joining Labcorp in 2021, she practiced general medical oncology, benign and malignant hematology at Northern Light Eastern Maine Medical Center and also served as principal investigator for several clinical trials, mostly breast cancer studies. She joined Labcorp in December 2021.

Wojciech Massalski, MD
Directeur médical

Wojciech Massalski, MD, is medical director for Labcorp Clinical Development Services, based in Maidenhead, U.K. He serves as global lead project physician on client projects, providing medical expertise and support in the development and conduct of clinical trials. Il s'agit notamment d'examiner la faisabilité pour les centres investigateurs et le recrutement des sujets de l'essai et de réaliser l'évaluation des risques de faisabilité et la surveillance de sécurité des données sur les projets qui lui sont assignés. Dr Massalski a plus de 20 ans d'expérience comme médecin, chercheur clinique et directeur médical. Before Labcorp, he was senior medical officer for Chiltern International in the U.K. He also has held clinical research and medical monitoring positions with Pfizer and Synexus Limited in the U.K. Dr. Massalski joined Labcorp in April 2019.

Maksym Novikov, MD
Directeur médical

Maksym Novikov, MD, is senior medical director for Labcorp Clinical Development Services, based in Maidenhead, U.K. He serves as global lead project physician on assigned projects, providing medical expertise and support in the development and conduct of clinical trials. This includes reviewing feasibility of investigator sites and recruitment of trial subjects and performing feasibility risk assessment and data safety monitoring; he also develops and reviews protocols, case report forms and other data and materials on assigned projects. Dr. Novikov has more than 20 years of experience as a physician (surgeon), clinical researcher and medical director. Before Labcorp, he was senior medical officer for Chiltern International in the U.K. He also has held clinical research and medical monitoring positions with Novartis, AstraZeneca and other drug development and healthcare organizations. He joined Labcorp in April 2019.

Valery Novikov, MD, PhD
Directeur médical principal

Valery Novikov, MD, PhD, is senior medical director for Labcorp Clinical Development Services, based in Paris, France. He is responsible for the medical strategy and execution of clients' clinical research projects. Dr Novikov vérifie les protocoles, les formulaires de rapport de cas, les rapports d'essais cliniques, les demandes d'autorisation de nouveaux médicaments, les valeurs des laboratoires, les effets secondaires, les tableaux de données et autres données et documents. He also is responsible for medical and safety monitoring on assigned projects and brings more than 20 years of national and international clinical research experience to Labcorp. Before joining Labcorp, Dr. Novikov served as clinical study director for Sanofi in France. He also has held clinical research positions with Generium, Helios Clinical Research and PRA International in Moscow, Russia. Dr. Novikov joined Labcorp in August 2019.

Maria Elvira Parellada, MD
Directrice médicale

Maria Elvira Parellada, MD, is medical director for Labcorp Clinical Development Services, based in Buenos Aires, Argentina. She provides subject matter expertise in hematology, supporting development of clinical trials and drug development. Dr. Parellada performs medical and safety monitoring on assigned projects and develops and reviews protocols, case report forms and other data and materials. Dr. Parellada has 10 years of experience as a hematologist physician; four years in clinical research as investigator in several clinical trials including acute and chronic myeloproliferative and lymphoproliferative disorders; and current experience as medical director in clinical research and development. She is a member of the Argentinian Society of Hematology. Before joining Labcorp, she served as hematology MSL for Janssen Pharmaceuticals in Argentina. She joined Labcorp in August 2021.

Martine Poelman, MD
Executive Medical Director

Martine Poelman, MD, is executive medical director of oncology for Labcorp Clinical Development Services, based in Brussels, Belgium. She provides medical and scientific support to help advance drug development in hematological malignancies for Labcorp clients. Dr. Poelman brings more than 30 years of experience in clinical research and development as a physician and medical director, specializing in pediatrics and oncology, to Labcorp. Before assuming her current position, Dr. Poelman served more than 15 years as global head of oncology research for Labcorp, providing medical monitoring for more than 200 clinical trials. Before joining Labcorp, she served as clinical research physician for hemato-oncology-infectiology at Eli Lilly in Brussels. Before going into research, she served as bone marrow transplantation and hemato-oncology physician for the department of pediatric oncology, Wilhelmina Children's Hospital, in the Netherlands. She joined Labcorp in November 1996.

Chia Portera, MD, PhD
Directrice médicale principale

Chia Portera, MD, PhD, is senior medical director for Labcorp Clinical Development Services, based in Princeton, New Jersey. Elle évalue et définit des stratégies de développement de médicaments pour les projets de recherche de nos clients et fournit son expertise clinique et scientifique aux équipes des projets. Dr. Portera develops, reviews and revises protocols, clinical trial reports, new drug applications, and other data and documents and is responsible for medical and safety monitoring on assigned projects. Elle a plus de 10 ans d'expérience en tant qu'oncologue médicale et directrice médicale dans la recherche et le développement cliniques. As a medical director at Genentech before joining Labcorp, Dr. Portera led clinical development strategies of postmarket therapies for treatment of HER2+ breast cancer. She joined Labcorp in July 2015.

Kamal Veer Singh Saini, MD
Directeur médical exécutif

Kamal Veer Singh Saini, MD, is executive medical director of oncology for Labcorp Clinical Development Services, based in Brussels, Belgium. He is a board-certified medical oncologist, with an active license to practice in the U.K. He contributes to the scientific strategic leadership of the Oncology area at Labcorp and provides clinical and medical expertise to project teams and other Labcorp departments on clients' drug development projects. He brings more than 15 years of experience in clinical research and development to Labcorp. He previously served as associate scientific director for an academic research organization and as medical advisor for Institute Jules Bordet, Brussels. The author or co-author of several peer-reviewed journal articles, he joined Labcorp in June 2015.

Irina Savina, MD, PhD
Directrice médicale

Irina Savina, MD, PhD, is medical director for Labcorp Clinical Development Services, based in St. Petersburg, Russian Federation. She serves as lead project physician on clients' drug development projects, provides medical/scientific expertise to project teams, reviews protocols and medical data and is responsible for medical and safety monitoring on assigned projects. Dr. Savina has more than 27 years of experience as a physician, research clinician and medical director with therapeutic experience in oncology. Before joining Labcorp, she was medical oncologist, lower GI surgeon, in St. Petersburg. She joined Labcorp in February 2010.

Laura Vidal, MD
Directrice médicale exécutive

Laura Vidal, MD, is executive medical director for Labcorp Clinical Development Services, based in Madrid, Spain. Dr. Vidal is the medical head of the Oncology group in EU. She contributes to the development of Labcorp policies involving medical, safety and therapeutics; serves as point of contact for key clients on business oversight; manages relationships with investigators/sites for clinical trials; and mentors clinical research physicians and medical directors across the company. Dr. Vidal has more than 15 years of experience as a physician, clinical oncologist and medical director. Before joining Labcorp, she was executive medical director for Syneos Health in Madrid and previously served as a physician, medical oncologist and clinical trials coordinator for a hospital in Barcelona. Dr Vidal est auteure et co-auteure de douzaines d'articles de publications scientifiques et a reçu de nombreux prix dans les domaines de la santé et de la recherche. She joined Labcorp in December 2020.

Liang Wan, MD, PhD
Directeur médical

Liang Wan, MD, PhD, is medical director for Labcorp Clinical Development Services, based in Shanghai, China. He serves as lead project physician on clients' drug development projects, provides medical/scientific expertise to project teams, reviews protocols and medical data and is responsible for medical and safety monitoring on assigned projects. Dr. Wan has more than 25 years of experience as a physician, research clinician and medical director with therapeutic experience in oncology, gastroenterology and hematology. Before joining Labcorp, he was medical director for IQVIA in Shanghai, serving as global or regional medical advisor on assigned projects. He began his career as a surgeon and clinical investigator at Shanghai Jiao Tong University RuiJin Hospital. Dr. Wan joined Labcorp in May 2019.

Howard Yeh, MD
Directeur médical

Howard Yeh, MD, is senior medical director (Los Angeles, California), based in Princeton, New Jersey. He presents medical/scientific capabilities to clients and participates in feasibility discussions related to project proposals, builds client relationships and relationships with investigators/sites for clinical trials and serves as lead project physician on clients' drug development projects. Dr Yeh a plus de 15 ans d'expérience comme directeur médical dans la recherche clinique et le développement de médicaments. Before joining Labcorp, he was medical director for Johnson & Johnson, Janssen Oncology Clinical Development Services, in Pennsylvania. He previously served as medical director for Amgen Clinical Development Services in California. The author or co-author of nearly two dozen peer-reviewed journal articles, Dr. Yeh joined Labcorp in May 2016.

Reigetsu Yoshikawa, MD, PhD
Directrice médicale principale

Reigetsu Yoshikawa, MD, PhD, is senior medical director for Labcorp Clinical Development Services, based in Osaka, Japan. She contributes to the development of medical strategies and execution of clients' clinical programs and provides medical/scientific expertise to project teams. Dr. Yoshikawa has more than 30 years of experience as a physician, medical director/advisor and professor of medicine in Japan. Before joining Labcorp, she was senior medical advisor for Eli Lilly and previously served as senior medical lead for Sumitomo Dainippon Pharma in Japan. Dr. Yoshikawa has served on the editorial boards of several peer-reviewed journals and has authored or co-authored dozens of articles, presentations and abstracts. She joined Labcorp in January 2021.